Abeona Therapeutics Inc ( (ABEO) ) has released its Q2 earnings. Here is a breakdown of the information Abeona Therapeutics Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases, with a notable product, ZEVASKYN™, approved for treating recessive dystrophic epidermolysis bullosa. In its latest earnings report for the quarter ended June 30, 2025, Abeona Therapeutics highlighted a significant financial turnaround, driven by the FDA approval of ZEVASKYN™ and the sale of a Priority Review Voucher. The company reported a net income of $108.8 million, a substantial increase from a net loss of $24.2 million in the same period last year, largely due to a $152.4 million gain from the sale of the voucher. Abeona’s cash and cash equivalents surged to $163.5 million from $23.4 million at the end of 2024, reflecting improved liquidity. Despite increased expenses in research and development and selling, general, and administrative areas, the company’s financial position strengthened significantly. Looking ahead, Abeona Therapeutics aims to leverage its enhanced financial position to advance its pipeline of gene therapies and expand its manufacturing capabilities, positioning itself for future growth in the biopharmaceutical sector.